PERSEUS Trial Design and Overview
Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.
EP: 1.Unmet Needs and Standards of Care in Multiple Myeloma
EP: 2.A Unique Drug Delivery Technology for MM
EP: 3.PERSEUS Trial Design and Overview
EP: 4.PERSEUS Trial Outcome Analysis
EP: 5.PERSEUS Trial Adverse Events and Safety Profiles
EP: 6.Integrating New Approaches to MM Treatment
EP: 7.Closing Perspectives on MM Treatment and Care
Summary
Brea C. Lipe, MD reviews the PERSEUS trial conducted by the European Myeloma Network. This trial was a phase three randomized trial of over 700 patients comparing a quadruplet regimen of lenalidomide, bortezomib, dexamethasone, and subcutaneous daratumumab (DARA) to a triplet without daratumumab (VRd) for 28-day cycles. After induction, patients went on to maintenance with lenalidomide and dexamethasone. Notably, patients in the Dara-VRd arm who were MRD negative for 12 consecutive months after 2 years maintenance were able to discontinue treatment. The trial demonstrated improved progression-free and overall survival with Dara-VRd compared to VRd. Recognizing these nuanced design and regimen details is important when interpreting the trial results and determining applicability.
Summary was AI-generated and edited for clarity.
